Mark Velleca, CEO of G1 Therapeutics, took the biotechnology company public on Wednesday, raising $105 million.
Mark Velleca, CEO of G1 Therapeutics, took the biotechnology company public on Wednesday, raising $105 million. Courtesy of G1 Therapeutics Special to The Herald-Sun
Mark Velleca, CEO of G1 Therapeutics, took the biotechnology company public on Wednesday, raising $105 million. Courtesy of G1 Therapeutics Special to The Herald-Sun

Research Triangle Park company debuts on Nasdaq

May 17, 2017 11:45 AM

More Videos

  • BASF RTP employees are tagging and releasing monarchs who will join the mass migration of butterflies heading for Mexico.

    BASF RTP employees are tagging and releasing monarchs who will join the mass migration of butterflies heading for Mexico.